Modulating 5-HT₄ and 5-HT₆ receptors in Alzheimer’s disease treatment

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Féger J, Hirsch EC. In search of innovative therapeutics for neuropsychiatric disorders: the case of neurodegenerative diseases. Ann. Pharm. Françaises 73, 3–12 (2015).
  Medline CASGoogle Scholar
• 2 Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J. Clin. Invest. 115, 1121–1129 (2005).
  Medline CASGoogle Scholar
• 3 Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev. Drug Discov. 6, 464–479 (2007).
  Medline CASGoogle Scholar
• 4 Lee WH, Loo CY, Bebawy M, Luk F, Mason RS, Rohanizadeh R. Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. Curr. Neuropharmacol. 11, 338–378 (2013).
  Medline CASGoogle Scholar
• 5 Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10(9), 698–712 (2011).
  Medline CASGoogle Scholar
• 6 Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9(7), 702–716 (2010).
  Medline CASGoogle Scholar
• 7 Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers. Res. Ther. 6, 37 (2014).
  MedlineGoogle Scholar
• 8 Thathiah A, De Strooper B. The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nat. Rev. Neurosci. 12(2), 73–87 (2011). • Role of G-protein-coupled receptor modulation in Alzheimer’s disease and description of amyloid precursor protein processing.
  Medline CASGoogle Scholar
• 9 Geldenhuys WJ, Van der Schyf CJ. Role of serotonin in Alzheimer's disease: a new therapeutic target? CNS Drugs 25(9), 765–781 (2011).
  Medline CASGoogle Scholar
• 10 Dumuis A, Bouhelal R, Sebben M, Cory R, Bockaert J. A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol. Pharmacol. 34(6), 880–887 (1988).
  Medline CASGoogle Scholar
• 11 Bockaert J, Claeysen S, Compan V, Dumuis A. 5-HT(4) receptors: history, molecular pharmacology and brain functions. Neuropharmacology 55, 922–931 (2008).
  Medline CASGoogle Scholar
• 12 Berthouze M, Ayoub M, Russo O et al. Constitutive dimerization of human serotonin 5-HT4 receptors in living cells. FEBS Lett. 579(14), 2973–2980 (2005).
  Medline CASGoogle Scholar
• 13 Claeysen S, Donneger R, Giannoni P, Gaven F, Pellissier LP. Serotonin type 4 receptor dimers. Methods Cell. Biol. 117, 123–139 (2013).
  Medline CASGoogle Scholar
• 14 Tack J, Camilleri M, Chang L et al. Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Aliment. Pharmacol. Ther. 35, 745–767 (2012).
  Medline CASGoogle Scholar
• 15 Eglen RM, Wong EHF, Dumuis A, Bockaert J. Central 5-HT4 receptors. Trends Pharmacol. Sci. 16, 391–398 (1995).
  Medline CASGoogle Scholar
• 16 Reynolds GP, Mason SL, Meldrum A et al. 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. Br. J. Pharmacol. 114, 993–998 (1995).
  Medline CASGoogle Scholar
• 17 Cachard-Chastel M, Devers S, Sicsic S et al. Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl/6j mice. Behav. Brain Res. 187, 455–461 (2008).
  Medline CASGoogle Scholar
• 18 Bockaert J, Claeysen S, Compan V, Dumuis A. 5HT(4)) receptors, a place in the sun: act two. Curr. Opin. Pharmacol. 11, 87–93 (2011).
  Medline CASGoogle Scholar
• 19 Furukawa K, Sopher BL, Rydel RE et al. Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J. Neurochem. 67, 1882–1896 (1996).
  Medline CASGoogle Scholar
• 20 Small DH, Nurcombe V, Reed G et al. A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth. J. Neurosci. 14(4), 2117–2127 (1994).
  Medline CASGoogle Scholar
• 21 Ishida A, Furukawa K, Keller JN, Mattson MP. Secreted form of beta-amyloid precursor protein shifts the frequency dependency for induction of LTD, and enhances LTP in hippocampal slices. Neuroreport 8, 2133–2137 (1997).
  Medline CASGoogle Scholar
• 22 Sennvik K, Fastbom J, Blomberg M, Wahlund LO, Winblad B, Benedikz E. Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 278, 169–172 (2000).
  Medline CASGoogle Scholar
• 23 Tippmann F, Hundt J, Schneider A, Endres K, Fahrenholz F. Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J. 23, 1643–1654 (2009).
  Medline CASGoogle Scholar
• 24 Jarvis CI, Clarke E, Dogruel M et al. Retinoic acid receptor-alpha signalling antagonizes both intracellular and extracellular amyloid-beta production and prevents neuronal cell death caused by amyloid-beta. Eur. J. Neurosci. 32, 1246–1255 (2010).
  Medline CASGoogle Scholar
• 25 Donmez G, Wang D, Cohen DE, Guarente L. SIRT1 suppresses beta-amyloid production by activating the alphasecretase gene ADAM10. Cell 142, 320–332 (2010).
  Medline CASGoogle Scholar
• 26 Robert SJ, Zugaza JL, Fischmeister R, Gardier AM, Lezoualc'h F. The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. J. Biol. Chem. 276(48), 44881–44888 (2001).
  Medline CASGoogle Scholar
• 27 Maillet M, Robert SJ, Cacquevel M et al. Crosstalk between Rap1 and Rac regulates secretion of sAPPalpha. Nat. Cell Biol. 5, 633–639 (2003).
  Medline CASGoogle Scholar
• 28 Cho S, Hu Y. Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. Exp. Neurol. 203, 274–278 (2007).
  Medline CASGoogle Scholar
• 29 Cochet M, Donneger R, Cassier E et al. 5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10. ACS Chem. Neurosci. 4, 130–140 (2013).
  Medline CASGoogle Scholar
• 30 Gherlardini C, Meoni P, Galleotti N, Malmberg-Aiello P, Rizzi CA, Bartolini A. Effect of the two benzimidazolone derivates: BIMU 1 and BIMU 8 on a model of hypoxia-induced amnesia in the mouse. Presented at: The Third IUPHAR Satellite Meeting on Serotonin. Chicago, IL, USA, 30 July–3 August 1994.
  Google Scholar
• 31 Letty S, Child R, Gale JD, Dumuis A, Bockaert J, Rondouin G. 5-HT4 receptors improve social olfactory memory in rat. Neuropharmacology 36, 681–687 (1997).
  Medline CASGoogle Scholar
• 32 Marchetti-Gauthier E, Roman FS, Dumuis A, Bockaert J, Soumireu-Mourat B. BIMU1 increases associative memory in rats by activating 5-HT4 receptors. Neuropharmacology 36, 697–706 (1997).
  Medline CASGoogle Scholar
• 33 Moser PC, Bergis OE, Jegham S et al. SL65.0155, a novel 5-hydroxytryptamine 4 receptor partial agonist with potent cognition-enhancing properties. J. Pharmacol. Exp. Ther. 302, 731–741 (2002).
  Medline CASGoogle Scholar
• 34 Micale V, Leggio GM, Mazzola C, Drago F. Cognitive effects of SL65.0155, a serotonin 5-HT4 receptor partial agonist, in animal models of amnesia. Brain Res. 1121(1), 207–215 (2006).
  Medline CASGoogle Scholar
• 35 Mohler EG, Shacham S, Noiman S et al. VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux. Neuropharmacology 53, 563–573 (2007).
  Medline CASGoogle Scholar
• 36 Brodney MA, Johnson DE, Sawant-Basak A et al. Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease. J. Med. Chem. 55(21), 9240–9254 (2012).
  Medline CASGoogle Scholar
• 37 Eglen RM, Bonhaus DW, Clark RD et al. Effects of a selective and potent 5-HT receptor agonist, RS-67333 and antagonist, RS-67352 in a rodent model of spatial learning and memory. Br. J. Pharmacol. 116, 235 (1995).
  Google Scholar
• 38 Fontana DJ, Daniels SE, Wong EHF, Clark RD, Eglen RM. The effects of novel, selective 5-hydroxytryptamine (5-HT)4 receptor ligands in rat spatial navigation. Neuropharmacology 36, 689–696 (1997).
  Medline CASGoogle Scholar
• 39 Marchetti E, Dumuis A, Bockaert J, Soumireu-Mourat B, Roman FS. Differential modulation of the 5-HT4 receptor agonists and antagonists on rat learning and memory. Neuropharmacology 39, 2017–2027 (2000).
  Medline CASGoogle Scholar
• 40 Lamirault L, Simon H. Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors. Neuropharmacology 41, 844–853 (2001).
  Medline CASGoogle Scholar
• 41 Lelong V, Lhonneur L, Dauphin F, Boulouard M. BIMU 1 and RS 7333, two 5-HT4 receptor agonists, modulate spontaneous alternation deficits induced by scopolamine in the mouse. Naunyn Schmiedebergs Arch. Pharmacol. 367, 621–628 (2003).
  Medline CASGoogle Scholar
• 42 Marchetti E, Chaillan FA, Dumuis A, Bockaert J, Soumireu-Mourat B, Roman FS. Modulation of memory processes and cellular excitability in the dentate gyrus offreely moving rats by a 5-HT4 receptors partial agonist, and an antagonist. Neuropharmacology 47, 1021–1035 (2004).
  Medline CASGoogle Scholar
• 43 Orsetti M, Dellarole A, Ferri S, Ghi P. Acquisition, retention, and recall of memory after injection of RS67333, a 5-HT(4) receptor agonist, into the nucleus basalis magnocellularis of the rat. Learn. Mem. 10(5), 420–426 (2003).
  MedlineGoogle Scholar
• 44 Giannoni P, Gaven F, De Bundel D et al. Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer's disease. Front. Aging Neurosci. 5(96), 1–12 (2013). •• Reduction of amyloid pathology in transgenic mice model after chronic administration of a 5-HT4R agonist.
  MedlineGoogle Scholar
• 45 Monsma DR, Shen FJ, Ward Y, Hamblin RP, Sibley MW. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 43, 320–327 (1993).
  Medline CASGoogle Scholar
• 46 Unsworth PB, Molinoff CD. Characterization of a 5-hydroxytryptamine receptor in mouse neuroblastoma N18TG2 cells. J. Pharmacol. Exp. Ther. 269, 246 (1994).
  Medline CASGoogle Scholar
• 47 Kohen MW, Metcalf R, Khan MA et al. Cloning, characterization and chromosomal localization of a human 5-HT6 serotonin receptor. J. Neurochem. 66, 47–56 (1996).
  Medline CASGoogle Scholar
• 48 Roberts JC, Reavill C, East SZ et al. The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]SB-258585. Brain Res. 934(1), 49–57 (2002).
  Medline CASGoogle Scholar
• 49 Sebben M, Ansanay H, Bockaert J, Dumuis A. 5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. Neuroreport 5, 2553–2557 (1994).
  Medline CASGoogle Scholar
• 50 Gérard C, Martres M, Lefèvre K et al. Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res. 746, 207–219 (1997).
  Medline CASGoogle Scholar
• 51 Dawson LA, Nguyen HQ, Li P et al. In Vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate. Br. J. Pharmacol. 130, 23–26 (2000).
  Medline CASGoogle Scholar
• 52 Dawson LA, Nguyen HQ, Li P. The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 25, 662–668 (2001).
  Medline CASGoogle Scholar
• 53 Tassone A, Madeo G, Schirinzi T et al. Activation of 5-HT6 receptors inhibits corticostriatal glutamatergic transmission. Neuropharmacology 61, 632–637 (2001).
  Google Scholar
• 54 Fone KCF. An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function. Neuropharmacology 55, 1015–1022 (2008).
  Medline CASGoogle Scholar
• 55 Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol. Ther. 117, 207–231 (2008).
  Medline CASGoogle Scholar
• 56 Ramírez MJ. 5-HT6 receptors and Alzheimer's disease. Alzheimers. Res. Ther. 5, 15 (2013).
  MedlineGoogle Scholar
• 57 Benhamú B, Martín-Fontecha M, Vázquez-Villa H, Pardo L, López-Rodríguez ML. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease. J. Med. Chem. 57, 7160–7181 (2014). • Review containing structure–activity relationship (SAR) studies of most 5-HT6R antagonists.
  Medline CASGoogle Scholar
• 58 Karila D, Freret T, Bouet V et al. Therapeutic potential of 5-HT 6 receptor agonists. J. Med. Chem. 58(20), 7901–7912 (2015). • Review containing a description of potential of 5-HT6R agonists.
  Medline CASGoogle Scholar
• 59 Sleight AJ, Boess FG, Bos M, Levet-Trafit B, Riemer C, Bourson A. Characterization of Ro 04–6790 and Ro 63–0563: potent and selective antagonists at human and rat 5-HT6 receptors. Br. J. Pharmacol. 124, 556–562 (1998).
  Medline CASGoogle Scholar
• 60 Bromidge SM, Brown AM, Clarke SE et al. 5-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist. J. Med. Chem. 42, 202–205 (1999).
  Medline CASGoogle Scholar
• 61 Glennon RA, Lee M, Rangisetty JB et al. 2-Substituted tryptamines: agents with selectivity for 5-HT6 serotonin receptors. J. Med. Chem. 43, 1011–1018 (2000).
  Medline CASGoogle Scholar
• 62 Bernotas RC, Antane S, Shenoy R et al. 3-(Arylsulfonyl)-1-(azacyclyl)-1H-indoles are 5-HT(6) receptor modulators. Bioorg. Med. Chem. Lett. 20(5), 1657–60 (2010).
  Medline CASGoogle Scholar
• 63 Nirogi R, Dwarampudi A, Kambhampati R et al. Rigidized 1-aryl sulfonyl tryptamines: synthesis and pharmacological evaluation as 5-HT6 receptor ligands. Bioorg. Med. Chem. Lett. 21(15), 4577–4580 (2011).
  Medline CASGoogle Scholar
• 64 Mattsson C, Svensson P, Boettcher H, Sonesson C. Structure-activity relationship of 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole analogues as 5-HT(6) receptor agonists. Eur. J. Med. Chem. 63, 578–588 (2013).
  Medline CASGoogle Scholar
• 65 Nirogi RVS, Deshpande AD, Kambhampati R et al. Indole-3-piperazinyl derivatives: novel chemical class of 5-HT(6) receptor antagonists. Bioorg. Med. Chem. Lett. 21(1), 346–349 (2011).
  Medline CASGoogle Scholar
• 66 Park CM, Choi J, Choi JH, Kim SY, Park WK, Seong CM. 1-(Arylsulfonyl)-2,3-dihydro-1H-quinolin-4-one derivatives as 5-HT(6) serotonin receptor ligands. Bioorg. Med. Chem. Lett. 21(2), 698–703 (2011).
  Medline CASGoogle Scholar
• 67 Ivachtchenko AV, Golovina ES, Kadieva MG et al. 2-Substituted 5,6-dimethyl-3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines: new series of highly potent and specific serotonin 5-HT6 receptor antagonists. Eur. J. Med. Chem. 46, 1189–1197 (2011).
  Medline CASGoogle Scholar
• 68 Elokdah HM, Greenfield AA, Liu K et al. US20070037802 A1 (2007).
  Google Scholar
• 69 Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics 5, 458–469 (2008).
  Medline CASGoogle Scholar
• 70 Arnt J, Bang-Andersen B, Grayson B et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int. J. Neuropsychopharmacol. 13, 1021–1033 (2010).
  Medline CASGoogle Scholar
• 71 ClinicalTrials.gov. Clinical Trials database: NCT00672945 https://clinicaltrials.gov/ct2/show/NCT00672945?term=PRX-03140&rank=3
  Google Scholar
• 72 ClinicalTrials.gov. Clinical Trials database: NCT01193062, NCT01173757, NCT01091272, NCT01169714, NCT01345864 https://clinicaltrials.gov/ct2/results?term=PF-04995274&Search=Search
  Google Scholar
• 73 Nicholas T, Duvvuri S, Leurent C et al. Systems pharmacology modeling in neuroscience: prediction and outcome of PF-04995274, a 5HT4 partial agonist, in a clinical scopolamine impairment trial. Adv. Alzheimer's Dis. 2(3), 83–98 (2013).
  Google Scholar
• 74 Bockaert J, Claeysen S, Compan V, Dumuis A. 5-HT4 receptors. Current drug targets. CNS Neurol. Disord. 3(1), 39–51 (2004).
  Medline CASGoogle Scholar
• 75 ClinicalTrials.gov. Clinical Trials database: NCT02575482, NCT03031574 https://clinicaltrials.gov/ct2/results?term=suvn-d4010&Search=Search
  Google Scholar
• 76 Askat, portfolio. http://askat-inc.com/portfolio/
  Google Scholar
• 77 Fujiuchi A, Sugiura A, Ohshiro H, Watanabe S, Yamamoto T, Take Y. RQ-00000009, a selective 5-HT4 receptor partial agonist, suppressed brain amyloid-b protein levels and improved memory and cognitive performances in rodents. Alzheimers Demen. 6, S53 (2010).
  Google Scholar
• 78 Bezprozvanny I. The rise and fall of Dimebon. Drug News Perspect. 23(8), 518–523 (2010).
  MedlineGoogle Scholar
• 79 Cano-Cuenca N, Solís-García A, Del Pozo JE, Jordán J. Evidence for the efficacy of latrepirdine (Dimebon) treatment for improvement of cognitive function: a meta-analysis. J. Alzheimers Dis. 38(1), 155–164 (2014).
  Medline CASGoogle Scholar
• 80 ClinicalTrials.gov. Clinical Trials database: NCT00224497, NCT00708552, NCT00551772, NCT00348192, NCT00710684 https://clinicaltrials.gov/ct2/results?term=SB-742457&Search=Search
  Google Scholar
• 81 ClinicalTrials.gov. Clinical Trials database: NCT02910102, NCT02586909, NCT02585934 https://clinicaltrials.gov/ct2/results?term=RVT-101&Search=Search
  Google Scholar
• 82 ClinicalTrials.gov. Clinical Trials database: NCT01253655 https://clinicaltrials.gov/ct2/show/NCT01253655?term=PF-05212365&rank=1
  Google Scholar
• 83 Clinical Trials database: NCT01712074. https://clinicaltrials.gov/ct2/show/NCT01712074
  Google Scholar
• 84 Avineuro pipeline consulted online at: www.avineuro.com/pipeline/
  Google Scholar
• 85 ClinicalTrials.gov. Clinical Trials database: NCT01908010 https://clinicaltrials.gov/ct2/show/NCT01908010?term=ABT-354&rank=1
  Google Scholar
• 86 Abbvie pipeline consulted online at: www.abbvie.com/our-science/pipeline.html
  Google Scholar
• 87 ClinicalTrials.gov. Clinical Trials database: NCT02580305 https://clinicaltrials.gov/ct2/show/NCT02580305?term=5-HT6&cond=Alzheimer&rank=2
  Google Scholar
• 88 Hekmatimoghaddam S, Zare-Khormizi MR, Pourrajab F. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases. Biofactors doi:10.1002/biof.1264 (2016) (Epub ahead of print).
  MedlineGoogle Scholar
• 89 Bhat AH, Dar KB, Anees S et al. Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight. Biomed. Pharmacother. 74, 101–110 (2015).
  Medline CASGoogle Scholar
• 90 Frautschy SA, Cole GM. Why pleiotropic interventions are needed for Alzheimer's disease. Mol. Neurobiol. 41, 392–409 (2010).
  Medline CASGoogle Scholar
• 91 Cavalli A, Bolognesi ML, Minarini A et al. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 51(3), 347–372 (2008).
  Medline CASGoogle Scholar
• 92 Lamirault L, Guillou C, Thal C, Simon H. Combined treatment with galanthaminium bromide, a new cholinesterase inhibitor, and RS67333, a partial agonist of 5-HT4 receptors, enhances place and object recognition in young adult and old rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 21, 185–195 (2003).
  Google Scholar
• 93 Freret T, Bouet V, Quiedeville A et al. Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5HT(4)receptor activation (RS67333) on object trecognition in mice. Behav. Brain Res. 230, 304–308 (2012).
  Medline CASGoogle Scholar
• 94 Lecoutey C, Hedou D, Freret T et al. Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. Proc. Natl Acad. Sci. USA 111(36), E3825–E3830 (2014). • First multitarget-directed ligand targeting the 5-HT4R with promnesiant activities.
  Medline CASGoogle Scholar
• 95 Rochais C, Lecoutey C, Gaven F et al. Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride. J. Med. Chem. 58, 3172–3187 (2015).
  Medline CASGoogle Scholar
• 96 Więckowska A, Kołaczkowski M, Bucki A et al. Novel multi-target-directed ligands for Alzheimer's disease: combining cholinesterase inhibitors and 5-HT6 receptor antagonists. Design, synthesis and biological evaluation. Eur. J. Med. Chem. 124, 63–81 (2016). • First report on cholinesterase inhibitors and 5-HT6 receptor antagonists as multitarget-directed ligands for Alzheimer’s disease.
  Medline CASGoogle Scholar
• 97 Quiedeville A, Boulouard M, Hamidouche K et al. Chronic activation of 5-HT4 receptors or blockade of 5-HT6 receptors improve memory performances. Behav. Brain Res. 293, 10–17 (2015).
  Medline CASGoogle Scholar
• 98 Yahiaoui S, Hamidouche K, Ballandonne C et al. Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease. Eur. J. Med. Chem. 121, 283–293 (2016).
  Medline CASGoogle Scholar